# Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia

> **NCT02745223** · PHASE2 · COMPLETED · sponsor: **Orasis Pharmaceuticals Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Presbyopia

## Interventions

- **DRUG:** PresbiDrops (CSF-1)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02745223
- **Lead sponsor:** Orasis Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02745223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02745223, "Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02745223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*